Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Value-based insurance design in cardiology: using "clinical nuance" to improve quality of care and contain costs.

Stecker EC, Riles EM, Fendrick AM.

J Am Coll Cardiol. 2012 Oct 30;60(18):1825-7. doi: 10.1016/j.jacc.2012.07.039. Epub 2012 Oct 3. No abstract available.

2.

The Canadian Cardiovascular Society and reference-based drug pricing.

Olley PM, McLaughlin PR.

Can J Cardiol. 1998 May;14(5):669-70. No abstract available.

PMID:
9627521
3.

A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Cardiovascular Society.

[No authors listed]

Can J Cardiol. 1997 Jan;13(1):33-45. English, French. No abstract available.

PMID:
9039063
4.

Coverage of drug costs: reference-based pricing.

McGregor M.

Can J Cardiol. 1998 May;14(5):666-8.

PMID:
9627520
5.

[Cardiovascular prevention in the over-80 age group is beneficial].

Stalenhoef AF.

Ned Tijdschr Geneeskd. 2008 Jan 5;152(1):26. Dutch.

PMID:
18240757
6.

The impact of reducing cardiovascular medication copayments on health spending and resource utilization.

Choudhry NK, Fischer MA, Avorn JL, Lee JL, Schneeweiss S, Solomon DH, Berman C, Jan S, Lii J, Mahoney JJ, Shrank WH.

J Am Coll Cardiol. 2012 Oct 30;60(18):1817-24. doi: 10.1016/j.jacc.2012.06.050. Epub 2012 Oct 3.

7.

Predictors of government subsidized pharmaceutical use in patients with diabetes or cardiovascular disease in a primary care setting: evidence from a prospective randomized trial.

Hirst NG, Whitty JA, Synnott RL, Eley DS, Scuffham PA.

J Med Econ. 2011;14(6):698-704. doi: 10.3111/13696998.2011.614304. Epub 2011 Sep 5.

PMID:
21892854
8.
9.

Crunch time for clinical cardiology.

Lewis RP.

Am Heart Hosp J. 2003 Winter;1(1):104-6. No abstract available.

PMID:
15785184
10.

[Cardiovascular pharmacology].

Ravens U, Erdmann E.

Dtsch Med Wochenschr. 2004 Apr 8;129(15):799. German. No abstract available.

PMID:
15054684
11.

Medical economics and the assessment of value in cardiovascular medicine: Part I.

Mark DB, Hlatky MA.

Circulation. 2002 Jul 23;106(4):516-20. No abstract available.

12.

Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.

Ademi Z, Liew D, Hollingsworth B, Steg PG, Bhatt DL, Reid CM; REACH Registry Investigators.

Am J Cardiovasc Drugs. 2010;10(2):85-94. doi: 10.2165/11530670-000000000-00000.

PMID:
20334445
13.

Health care utilization and costs for diseases of the circulatory system in a corporate setting.

Tsai SP, Bernacki EJ, Reedy SM, Miller KE.

Prev Med. 1988 Jan;17(1):1-11.

PMID:
3362795
14.
15.

Managed care in cardiology.

Palank EA.

J Cardiovasc Manag. 1997 Jan-Feb;8(1):18-20.

PMID:
10165391
16.

Predictive modeling of health care costs: do cardiovascular risk markers improve prediction?

Baumeister SE, Dörr M, Radke D, Nauck M, John U, Marschall P, Flea S, Schmidt CO, Alte D, Völzke H.

Eur J Cardiovasc Prev Rehabil. 2010 Jun;17(3):355-62. doi: 10.1097/HJR.0b013e328333a0b7.

PMID:
19907337
17.

Access to quality cardiovascular care.

Richard Conti C.

Clin Cardiol. 2010 Feb;33(2):60-1. doi: 10.1002/clc.20748.

19.

Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.

Huse DM, Song X, Ozminkowski RJ, Maguire J, Williams SA, Borok GM, McDonough K.

Clin Ther. 2006 Sep;28(9):1425-42.

PMID:
17062315
20.

Economic evaluation in the field of cardiology: theory and practice.

van Hout BA, Goes ES, Grijseels EW, van Ufford MA.

Prog Cardiovasc Dis. 1999 Sep-Oct;42(2):167-73. Review.

PMID:
10555117

Supplemental Content

Support Center